Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Condition·Updated Jun 24, 2026·v1

Cervical Cancer v2 Radiation Management

Cervical cancer radiation management rests on a curative-definitive paradigm: IMRT/VMAT external-beam radiotherapy (45–50.4 Gy in 25–28 fractions) with concurrent weekly cisplatin 40 mg/m², capped by MRI-guided adaptive brachytherapy delivering HR-CTV D90 ≥85 Gy EQD2 with hard D2cc limits for rectum/sigmoid (≤75 Gy) and bladder (≤90 Gy). EMBRACE-I confirms 5-year local control of 91% and OS of 74% with this regimen, while PARCER established IMRT over 3D-CRT by demonstrating a 38% relative reduction in late GI toxicity. Postoperatively, Peters-positive (high-risk) disease mandates concurrent cisplatin-CRT per GOG-109, while Sedlis-positive (intermediate-risk) disease receives RT alone per GOG-263. Hypofractionation (POHIM_P3, SWIFT-1), immunotherapy-CRT combinations (CALLA, NRG GY-017), and prophylactic para-aortic irradiation (PRO-PARA) remain under prospective evaluation. The global equity gap in brachytherapy access — fewer than one center per 1,000 incident cases in LMICs, where 85% of incidence sits — remains the defining implementation challenge.

High Evidence181 references·1,452 words·6 min read·v1
cervical cancerradiation oncologybrachytherapyimage-guided adaptive brachytherapyIGABTIMRTVMATchemoradiationcisplatinFIGO 2018Peters criteriaSedlis criteriaEMBRACEEBRTgynecologic oncology

Quick Reference

RxDrug of choiceWeekly cisplatin 40 mg/m² IV × 5–6 cycles concurrent with EBRT (cumulative 200–240 mg/m²)
AltAlternativesNedaplatin 30 mg/m² weekly (less nephrotoxic, non-inferior 3-yr OS); lobaplatin 30 mg/m² q3 weekly (better completion in ≥65 yr); carboplatin in palliative or cisplatin-ineligible settings
⊘AvoidCisplatin when eGFR <60 mL/min, hearing loss, or peripheral neuropathy is significant; concurrent bevacizumab with pelvic reirradiation (fistula risk); omission of brachytherapy when curative intent is possible
DxTest of choiceMRI-guided adaptive brachytherapy (IGABT) with HR-CTV D90 ≥85 Gy EQD2 (α/β = 10) summed across EBRT + brachytherapy, validated by EMBRACE-I for 5-year local control of 91%
ScKey scorePeters criteria (high-risk post-op: nodes+, margins+, parametrium+ → concurrent CRT); Sedlis criteria (intermediate-risk post-op: ≥3 of deep stromal invasion >½, LVSI, tumour ≥4 cm → RT alone per GOG-263); Moore criteria (advanced disease: Black race, ECOG 1, pelvic-only disease, prior platinum, PFI <365 d → median OS 23.5 mo low-risk vs 10.0 mo high-risk)
→When to referTo a brachytherapy-equipped center if local IGABT capability is unavailable (EBRT alone halves cure rate); to gynecologic oncology for fertility-sparing surgery in IA1–IB1; to clinical trials for hypofractionation, immunotherapy-CRT combinations (NRG GY-017 atezolizumab template), or prophylactic para-aortic irradiation (PRO-PARA)
Definitive CRT with weekly cisplatin plus MRI-guided adaptive brachytherapy achieves >90% 5-year local control in locally advanced cervical cancer — brachytherapy is the dose-defining, non-substitutable curative step, and IMRT has replaced 3D-CRT after PARCER demonstrated a 38% relative reduction in late GI toxicity.
Radiation management of [[cervical cancer]] is stage-dependent, combining [[external beam radiotherapy]] with image-guided adaptive [[brachytherapy]] (IGABT) and concurrent cisplatin-based chemotherapy. Definitive chemoradiation is standard for FIGO 2018 IIB–IVA disease; adjuvant RT is guided by Peters (high-risk) and Sedlis (intermediate-risk) criteria. Modern IMRT/VMAT with daily CBCT has reduced late toxicity versus 3D-CRT.

Overview and Recommendations

Background

  • •Cervical cancer ranks 4th among female malignancies globally (~660,000 new cases, ~350,000 deaths annually) — radiotherapy is the curative backbone for most FIGO 2018 IIB–IVA presentations and the adjuvant standard for high-risk post-hysterectomy pathology, with global incidence concentrated in LMICs where the radiation infrastructure gap is most acute.
  • •The paradigm shift of two decades: from 3D-conformal pelvic RT with low-dose-rate brachytherapy to MRI-guided with adaptive image-guided brachytherapy (IGABT) per the GEC-ESTRO/EMBRACE consensus — yielding 5-year local control of 91% and OS of 74% in EMBRACE-I across 24 centers, with HR-CTV D90 and histology emerging as the dominant predictors of local failure.
  • •Concurrent weekly 40 mg/m² with pelvic RT adds a 6% absolute 5-year survival benefit (HR 0.81, NNT ≈ 17 to prevent one death at 5 years) per the 2008 individual-patient-data meta-analysis of 18 randomized trials, crystallized by GOG 85/120/123 and RTOG 90-01 and never subsequently displaced by a superior concurrent agent in biomarker-unselected disease.
  • • is the dose-defining curative step — its steep dose gradient delivers cumulative HR-CTV D90 ≥85 Gy EQD2 (α/β = 10) to the residual tumor while sparing rectum, bladder, and sigmoid; without it, even optimal EBRT halves the local cure rate, an asymmetry external-beam photons cannot replicate.
  • •Postoperative risk stratification bifurcates adjuvant decisions: Peters criteria (high-risk: positive nodes, margins, or parametrium → mandatory concurrent CRT) versus Sedlis criteria (intermediate-risk: ≥3 of deep stromal invasion >½, LVSI, or tumour ≥4 cm → RT alone per GOG-263) — a distinction the radiation oncologist must internalize before simulation.
  • • access is the global rate-limiting resource — a Lancet Oncology 2026 population-based analysis found LMICs, where 85% of cervical cancer incidence sits, have fewer than one brachytherapy center per 1,000 incident cases, defining the central implementation gap between curative intent and actual delivery worldwide.

Evaluation

  • •Triage by FIGO 2018 stage and clinical setting: IA1–IB1 low-risk → surgery ± Sedlis-triggered adjuvant RT; IB2–IIB node-positive or IIB–IVA → definitive CRT + IGABT (Category 1 NCCN); IIIA–IIIC2 → definitive CRT + brachytherapy ± extended-field IMRT; high-risk post-op (Peters) → adjuvant CRT with weekly cisplatin; IVB or recurrent → palliative whole-pelvic RT ± systemic therapy.
  • •Order pre-treatment /CT and pelvic for all locally advanced disease — nodal status (sensitivity ~75–90% for nodes ≥5 mm), parametrial extension, uterine body involvement, and hydronephrosis (which upstages to IIIB per FIGO 2018) collectively drive both target definition and prognosis.
  • •Consider laparoscopic or extraperitoneal para-aortic node sampling when is negative but high-risk features are present — occult para-aortic metastases are found in 12–22% of patients with FDG-avid pelvic nodes, and surgical staging informs extended-field IMRT coverage up to T12.
  • •Apply Peters (high-risk) criteria post-hysterectomy — positive nodes, positive margins, or parametrial involvement mandates concurrent CRT with weekly 40 mg/m² (GOG-109/SWOG-8797 standard, HR 0.48 for PFS); apply Sedlis (intermediate-risk) criteria — ≥3 of deep stromal invasion >½, LVSI, or tumour ≥4 cm — to identify candidates for adjuvant RT alone (GOG-263 supports omission of cisplatin in this population).
  • •Assess baseline renal function (eGFR ≥60 mL/min), audiometry, and peripheral neuropathy before weekly ; substitute nedaplatin 30 mg/m² weekly (non-inferior OS, less nephrotoxic) or lobaplatin 30 mg/m² q3 weekly (83.9% completion vs 54.5% in women ≥65) when renal function or tolerance precludes cisplatin.
  • •Simulate supine with custom immobilization, comfortably full bladder (reduces small-bowel dose), empty rectum, and a vaginal marker for cervical delineation; fuse diagnostic and /CT to the planning CT to guide CTV definition and nodal boost selection.
  • •Define the nodal CTV per the EMBRACE/GEC-ESTRO consensus: common iliac, external iliac, internal iliac, obturator, and presacral nodes (above S1–S2 for any cervical primary); extend cranially to T12 for para-aortic disease to deliver 45 Gy with concurrent cisplatin.
  • •Boost FDG-avid or pathologic nodes to 55–60 Gy in 25 fractions via simultaneous integrated boost or sequential cone-down per NRG GY-017 credentialing; contour OARs (small-bowel bag, rectum, bladder, sigmoid, femoral heads, bone marrow) with cumulative D2cc limits ≤75 Gy EQD2 (rectum/sigmoid) and ≤90 Gy EQD2 (bladder) summed across EBRT + brachytherapy.
  • •Plan or with daily — PARCER phase III established that image-guided IMRT reduces 3-year grade ≥2 late GI toxicity from 49.5% to 27.5% versus (HR 0.46) in the postoperative setting, anchoring the modern bowel-sparing standard of care.
  • •Select the brachytherapy applicator by residual anatomy: tandem-and-ovoid for HR-CTV <4 cm; tandem-and-ring for rectal-sparing priority (slightly lower rectal D2cc); hybrid intracavitary/interstitial (IC/IS) for bulky residual or parametrial extension, used in 43% of EMBRACE-I patients. Acquire T2-weighted at each fraction for HR-CTV and IR-CTV delineation; CT-based planning is an acceptable fallback where MRI access is constrained.

Management

  • •Initiate / with daily as the EBRT standard — replaces in NCCN and ASTRO guidelines and reduces late GI toxicity per PARCER (HR 0.62 for grade ≥2 late GI events at 3 years).
  • •Deliver conventional fractionation: 45–50.4 Gy in 25–28 fractions (1.8 Gy/fx) to the pelvis ± para-aortic chain; boost involved nodes to 55–65 Gy via SIB or sequential cone-down. Reserve hypofractionated regimens (postoperative 40 Gy/16 fx per POHIM-CCRT; definitive 44 Gy/20 fx per HYPOCx-iRex) for protocol use only until POHIM_P3 and SWIFT-1 report.
  • •Administer weekly 40 mg/m² IV on day 1 of each RT week for 5–6 cycles (cumulative 200–240 mg/m²) with vigorous hydration and triple antiemetic prophylaxis — fosaprepitant 150 mg IV + palonosetron 0.25 mg + dexamethasone 8 mg achieves complete emesis prevention in 65% of patients per the GAND-emesis phase III trial.
  • •Add primary pegylated G-CSF prophylaxis in patients at high risk of myelosuppression — reduces grade 3–4 neutropenia from 42.5% to 22.5%, improves chemotherapy completion, and prolongs PFS in a 240-patient cohort; reserve for age ≥65, prior chemotherapy, or baseline neutropenia.
  • •Substitute nedaplatin 30 mg/m² weekly (non-inferior 3-year OS to cisplatin with less nephrotoxicity, HR 0.13 95% CI 0.016–1.07) or lobaplatin 30 mg/m² q3 weekly (83.9% vs 54.5% chemotherapy completion in women ≥65) when eGFR, hearing loss, or neuropathy precludes cisplatin.
  • •Trigger adaptive replanning when uterine shift exceeds 5 mm, OARs encroach on tolerance, or tumor regression exceeds 20% — progressive shrinkage often mandates mid-treatment replanning in IIIC2 disease, and library-based plan-of-the-day ART reduces uterine motion–related dosimetric error.
  • •Plan MRI-guided adaptive starting week 5 of EBRT: 4 HDR fractions of 7 Gy each (28 Gy total), twice weekly, using tandem-and-ovoid, tandem-and-ring, or hybrid IC/IS applicators adapted to the residual anatomy at each fraction.
  • •Prescribe HR-CTV D90 ≥85 Gy EQD2 (α/β = 10) summed across EBRT + brachytherapy; maintain rectum/sigmoid D2cc ≤75 Gy EQD2 and bladder D2cc ≤90 Gy EQD2 (α/β = 3). Each 5 Gy increase in HR-CTV D90 yields roughly 3–4% absolute gain in 5-year local control across the EMBRACE dose range.
  • •For post-hysterectomy high-risk disease (Peters-positive — nodes, margins, or parametrium): adjuvant CRT with weekly 40 mg/m² × 6 — non-negotiable standard set by GOG-109/SWOG-8797 (PFS HR 0.48) and confirmed by the STARS trial. For intermediate-risk disease (Sedlis-positive): adjuvant RT alone 45–50.4 Gy per GOG-263 — no significant RFS advantage from added cisplatin in this population.
  • •For palliation of bleeding, pain, or discharge in or recurrent disease: 30 Gy/10 fractions or 39.75 Gy/15 fractions whole-pelvic RT achieves rapid hemostasis in 80–90% of bleeding patients; consolidative pelvic RT after systemic therapy improves overall survival in newly diagnosed metastatic disease.
  • •Initiate Saccharomyces boulardii 250 mg/day one week before radiotherapy to reduce grade ≥2 acute diarrhea (RCT, n=60). Expect grade ≥2 diarrhea in 40–60% and proctitis in 20–30% during CRT; monitor weekly CBC — grade ≥2 lymphopenia is nearly universal and the CD4 nadir <200/μL by week 4 correlates with inferior tumor control.
  • •Avoid concurrent with pelvic reirradiation — amplifies the baseline <2% risk of rectal and bladder fistulas (GOG phase II, BEATcc). Counsel patients on lifelong risks: pelvic insufficiency fractures in 10–20% (screen with baseline L1 CT attenuation), vaginal stenosis (dilator use mandatory), and small but real secondary rectal cancer risk rising with extended follow-up.
  • •Refer for access if the local center lacks IGABT capability — EBRT alone halves the cure rate, and there is no acceptable substitute for intracavitary dose escalation in intact disease. Schedule first surveillance at 6–8 weeks with PET/CT and pelvic , then q3–6 months × 2 years, q6–12 months × 5 years; surveillance detects relapse a median of 18 months before clinical disease per CALLA phase III.

Board Review — High Yield

  • •EMBRACE-I — 5-year LC 91%, OS 74% with definitive CRT + MRI-IGABT in locally advanced cervical cancer (n=1,318 across 24 centers).
  • •HR-CTV D90 ≥85 Gy EQD2 — the dose-defining brachytherapy target; each 5 Gy D90 increase yields roughly 3–4% absolute 5-year local control gain across the EMBRACE dose range.
  • •PARCER phase III — image-guided IMRT reduced 3-year grade ≥2 late GI toxicity from 49.5% to 27.5% versus 3D-CRT (HR 0.46), establishing IMRT/VMAT + daily CBCT as the postoperative standard.
  • •NNT = 17 — concurrent weekly cisplatin adds a 6% absolute 5-year survival benefit (HR 0.81) per the 2008 IPD meta-analysis of 18 randomized trials.
  • •Peters criteria — high-risk post-op disease (nodes+, margins+, or parametrium+) mandates adjuvant CRT with cisplatin (GOG-109/SWOG-8797, PFS HR 0.48).
  • •Sedlis / GOG-263 — intermediate-risk post-op disease (≥3 of LVSI, depth >½, size ≥4 cm) receives adjuvant RT alone; no significant RFS benefit from adding cisplatin in this population.
  • •D2cc OAR limits — rectum/sigmoid ≤75 Gy EQD2, bladder ≤90 Gy EQD2 (α/β = 3) summed across EBRT + brachytherapy.
  • •Brachytherapy access gap — LMICs have <1 brachytherapy center per 1,000 incident cases (Lancet Oncology 2026); without brachytherapy, the cure rate is approximately halved.
  • •ctDNA surveillance (CALLA) — detects relapse a median of 18 months before clinical disease, redefining post-CRT surveillance timing.
  • •Moore criteria — 5-factor prognostic model (Black race, ECOG 1, pelvic-only disease, prior platinum, PFI <365 d) partitions median OS from 23.5 mo (low-risk) to 10.0 mo (high-risk) in advanced/recurrent disease.

Deep Dive — Evidence Details

References

  1. [1]

    Koh WJ, Abu-Rustum NR, Bean S et al.. “Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659131 ↗

    L1GUIDELINECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  2. [2]

    Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486458 ↗

    L1GUIDELINECited in: Indications by Stage, Concurrent Chemoradiation
  3. [3]

    Ryu SY, Deng W, Albuquerque K et al.. “Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40947016 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT, Outcomes
  4. [4]

    Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  5. [5]

    Sugiyama T, Fujiwara K, Ohashi Y et al.. “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24569914 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  6. [6]

    Cetina L, González-Enciso A, Cantú D et al.. “Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23609186 ↗

    L1RCTCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  7. [7]

    Sehouli J, Runnebaum IB, Fotopoulou C et al.. “A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22357252 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  8. [8]

    Kenter GG, Greggi S, Vergote I et al.. “Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656948 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  9. [9]

    Chopra S, Gupta S, Kannan S et al.. “Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34506246 ↗

    L1RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Concurrent Chemoradiation, Adjuvant and Palliative RT, Acute and Late Toxicity
  10. [10]

    da Costa SCS, Bonadio RC, Gabrielli FCG et al.. “Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31449470 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  11. [11]

    Dueñas-González A, Zarbá JJ, Patel F et al.. “Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21444871 ↗

    L1RCTCited in: Indications by Stage
  12. [12]

    Blohmer JU, Paepke S, Sehouli J et al.. “Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21860000 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  13. [13]

    Zuliani AC, Esteves SC, Teixeira LC et al.. “Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24449243 ↗

    L1RCTCited in: Indications by Stage, Brachytherapy
  14. [14]

    Ryu SY, Nam BH, Kim MH et al.. “A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.” ESMO open (2026). PMID: 41812622 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  15. [15]

    Yang X, Ren H, Li Z et al.. “A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.” ESMO open (2022). PMID: 35994789 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  16. [16]

    Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  17. [17]

    Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  18. [18]

    Ruhlmann CH, Christensen TB, Dohn LH et al.. “Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.” The Lancet. Oncology (2016). PMID: 26952945 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  19. [19]

    . “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗

    L1SR_OBSCited in: Indications by Stage, Adjuvant and Palliative RT, Outcomes
  20. [20]

    Huang H, Feng YL, Wan T et al.. “Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33443541 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT, Outcomes
  21. [21]

    Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗

    L2RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Concurrent Chemoradiation
  22. [22]

    Andrade MO, Al-Alam OCM, Kim HJS et al.. “Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2025). PMID: 40408847 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  23. [23]

    Tzioras S, Pavlidis N, Paraskevaidis E et al.. “Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis.” Cancer treatment reviews (2007). PMID: 17112673 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  24. [24]

    Petrelli F, Riboldi V, Bruschieri L et al.. “First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis.” Cancer treatment reviews (2025). PMID: 40086103 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  25. [25]

    Marchetti C, Fagotti A, Tombolini V et al.. “Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 31838220 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  26. [26]

    Rombouts AJM, Hugen N, van Beek JJP et al.. “Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.” Cancer treatment reviews (2018). PMID: 29957373 ↗

    L1SR_OBSCited in: Indications by Stage, Acute and Late Toxicity
  27. [27]

    de la Rochefordiere A, Kamal M, Floquet A et al.. “PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25724520 ↗

    L1RCTCited in: Indications by Stage, Outcomes
  28. [28]

    Nakano T, Suzuki Y, Ohno T et al.. “Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609033 ↗

    L4RCTCited in: Indications by Stage, Outcomes
  29. [29]

    Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗

    L2TRIAL_NONRANDOMCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  30. [30]

    Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Concurrent Chemoradiation
  31. [31]

    Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗

    L2COHORTCited in: Indications by Stage, Adjuvant and Palliative RT, Outcomes
  32. [32]

    Bertolazzi M, Genta ML, Lopes A et al.. “Randomized trial of autologous ovarian graft to preserve ovarian function in young women undergoing pelvic radiotherapy for cervical cancer.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41759360 ↗

    L1RCTCited in: Indications by Stage
  33. [33]

    Corbeau A, Spampinato S, Charnalia M et al.. “Normal tissue complication probability models for gastrointestinal toxicity after adjuvant (chemo)radiotherapy for cervical cancer in the PARCER trial.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41698508 ↗

    L2RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Concurrent Chemoradiation, Acute and Late Toxicity
  34. [34]

    Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  35. [35]

    Flint ML, Byrne ME, Friedman CF. “Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671446 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  36. [36]

    Xiang M, Kidd EA. “Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31390586 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  37. [37]

    Loiselle C, Koh WJ. “The emerging use of IMRT for treatment of cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147905 ↗

    L5OTHERCited in: Indications by Stage, External Beam Radiotherapy (EBRT)
  38. [38]

    Papadopoulos KP, Johnson ML, Lockhart AC et al.. “First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796520 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  39. [39]

    Nogueira-Rodrigues A, do Carmo CC, Viegas C et al.. “Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18829516 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  40. [40]

    Kunos CA, Waggoner S, von Gruenigen V et al.. “Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20145183 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Concurrent Chemoradiation
  41. [41]

    Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗

    L4CASE_REPORTCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  42. [42]

    . “Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA).” Trials (2026). PMID: 41792812 ↗

    L1RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Brachytherapy, Concurrent Chemoradiation
  43. [43]

    Bonala SR, Raja SA, Subramanian BV et al.. “Randomized comparison of tandem-ring versus tandem-ovoid applicators in volume-based brachytherapy for cervical cancer: Dosimetric analysis and early clinical outcomes.” Brachytherapy (2026). PMID: 41679999 ↗

    L1RCTCited in: Indications by Stage, Brachytherapy
  44. [44]

    Yokoi A, Machida H, Okazawa-Sakai M et al.. “Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 42012622 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT
  45. [45]

    Zhou L, Sun C, Diao P et al.. “Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.” Frontiers in immunology (2026). PMID: 41869324 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  46. [46]

    Hathout L, Zhang Y, Lymberis S et al.. “A Systematic Review of Patient-Reported Outcomes on the Impact of Radiation Therapy on Sexual Health in Patients With Gynecologic Cancer.” International journal of radiation oncology, biology, physics (2026). PMID: 41720168 ↗

    L2SR_OBSCited in: Indications by Stage
  47. [47]

    Chargari C, Martinez A, Michels J et al.. “[French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer].” Bulletin du cancer (2026). PMID: 41617621 ↗

    L1GUIDELINECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  48. [48]

    Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  49. [49]

    Schmid MP, Lindegaard JC, Mahantshetty U et al.. “Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36599120 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  50. [50]

    Dryden-Peterson S, Bvochora-Nsingo M, Suneja G et al.. “HIV Infection and Survival Among Women With Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27573661 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  51. [51]

    Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  52. [52]

    Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2022). PMID: 34773774 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  53. [53]

    Wieringa HW, van der Zee AG, de Vries EG et al.. “Breaking the DNA damage response to improve cervical cancer treatment.” Cancer treatment reviews (2016). PMID: 26643553 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  54. [54]

    Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  55. [55]

    Gouy S, Morice P, Narducci F et al.. “Nodal-staging surgery for locally advanced cervical cancer in the era of PET.” The Lancet. Oncology (2012). PMID: 22554549 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation
  56. [56]

    Westerveld H, Nesvacil N, Fokdal L et al.. “Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer.” The Lancet. Oncology (2020). PMID: 32135119 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  57. [57]

    Elbanna M, Pynda Y, Kalinchuk O et al.. “Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data.” The Lancet. Oncology (2023). PMID: 37657478 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Brachytherapy
  58. [58]

    Hajeer A, Salem A, Akash M et al.. “Assessing the global demand and supply of brachytherapy resources: a population-based observational study.” The Lancet. Oncology (2026). PMID: 41785895 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy
  59. [59]

    Elmore SNC, Polo A, Bourque JM et al.. “Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs.” The Lancet. Oncology (2021). PMID: 34478675 ↗

    L5OTHERCited in: Indications by Stage
  60. [60]

    Rodin D, Burger EA, Atun R et al.. “Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.” The Lancet. Oncology (2019). PMID: 31151906 ↗

    L2OTHERCited in: Indications by Stage
  61. [61]

    Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2017). PMID: 27993569 ↗

    L2OTHERCited in: Indications by Stage
  62. [62]

    Du Q, Liu Q, Zhou Y et al.. “Primary prophylaxis with pegylated G-CSF is associated with improved treatment completion and progression-free survival in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study.” Future oncology (London, England) (2026). PMID: 41930746 ↗

    L2COHORTCited in: Indications by Stage, Concurrent Chemoradiation
  63. [63]

    Malikova H, Graffneter K, Kremenova K et al.. “Pretreatment computed tomography L1 attenuation values: Easy reaching predicting factor for radiation-related bone insufficiency fractures in females treated for advanced cervical cancer (prospective study).” Women's health (London, England) (2026). PMID: 41746818 ↗

    L2COHORTCited in: Indications by Stage, Acute and Late Toxicity
  64. [64]

    Agustí N, Viveros-Carreño D, Wu CF et al.. “Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.” JAMA oncology (2025). PMID: 40079948 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT
  65. [65]

    Wang Y, Farmer M, Izaguirre EW et al.. “Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer.” JAMA oncology (2018). PMID: 30054609 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  66. [66]

    Colbert LE, El Alam MB, Wang R et al.. “Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring.” Cancer cell (2023). PMID: 37863066 ↗

    L5OTHERCited in: Indications by Stage
  67. [67]

    Zeng Z, Yang X, Wang W et al.. “Effect of Cisplatin Cycles on Prognosis for Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy: A Retrospective Cohort Study.” Technology in cancer research & treatment (2026). PMID: 42015673 ↗

    L2COHORTCited in: Indications by Stage
  68. [68]

    Mondini M, Deutsch E. “(Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33986023 ↗

    L5OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  69. [69]

    Lukovic J, Pintilie M, Han K et al.. “An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38180733 ↗

    L2OTHERCited in: Indications by Stage
  70. [70]

    Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  71. [71]

    Chaudary N, Pintilie M, Jelveh S et al.. “Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 27697997 ↗

    L5OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  72. [72]

    Chen J, Chen C, Zhan Y et al.. “Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33766815 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  73. [73]

    Ju XZ, Yang JM, Zhou XY et al.. “EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18223224 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy
  74. [74]

    Lee J, Chang CL, Lin JB et al.. “Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29959140 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  75. [75]

    Dankulchai P, Prasartseree T, Sittiwong W et al.. “Early Results of Hypofractionated Chemoradiation in Cervical Cancer with 44 Gy/ 20 F vs 45 Gy/ 25 F: A Phase II, Open-Label, Randomised Controlled Trial (HYPOCx-iRex Trial).” Clinical oncology (Royal College of Radiologists (Great Britain)) (2025). PMID: 40897075 ↗

    L1RCTCited in: External Beam Radiotherapy (EBRT)
  76. [76]

    Cho WK, Park W, Lee JH et al.. “Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial).” Journal of gynecologic oncology (2026). PMID: 40676909 ↗

    L1TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT)
  77. [77]

    Zeng Z, Chen Y, Qiu J et al.. “Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study.” Radiation oncology (London, England) (2025). PMID: 40671096 ↗

    L1TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT)
  78. [78]

    Cho WK, Park W, Kim SW et al.. “Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).” Gynecologic oncology (2025). PMID: 40449127 ↗

    L2TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT), Adjuvant and Palliative RT
  79. [79]

    You J, Wu D, Tie J et al.. “Phase I clinical trial of lobaplatin combined with image-guided volume-modulated arc radiation therapy in locally advanced cervical cancer.” BMC cancer (2026). PMID: 42168915 ↗

    L4TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT), Brachytherapy
  80. [80]

    Lebret D, Lafond C, Leseur J et al.. “Prospective multi-institutional study of library-based adaptive radiotherapy for cervical cancer: Evaluation of plan-of-the-day selection and population analysis.” Journal of applied clinical medical physics (2025). PMID: 41253687 ↗

    L2TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT)
  81. [81]

    Ma J, Wang G, Wang W et al.. “Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.” Journal of gynecologic oncology (2026). PMID: 42210768 ↗

    L2COHORTCited in: External Beam Radiotherapy (EBRT), Brachytherapy, Concurrent Chemoradiation
  82. [82]

    Riggenbach E, Mose L, Imboden S et al.. “Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study.” Journal of gynecologic oncology (2026). PMID: 41413788 ↗

    L3COHORTCited in: External Beam Radiotherapy (EBRT), Brachytherapy
  83. [83]

    Manea E, Anghel B, Stanescu AD et al.. “Adaptive Target Volume and Dosimetry in Image-Guided Radiotherapy for Cervical Cancer.” Journal of clinical medicine (2025). PMID: 40429413 ↗

    L4CASE_REPORTCited in: External Beam Radiotherapy (EBRT)
  84. [84]

    Xu M, Kang K, Zhao M et al.. “Optimizing ovarian dose sparing for young cervical cancer patients after oophoropexy: a dosimetric and radiobiological comparison of three radiotherapy techniques (IMPT, TOMO, and VMAT).” Radiation oncology (London, England) (2026). PMID: 42243980 ↗

    L4OTHERCited in: External Beam Radiotherapy (EBRT)
  85. [85]

    Mayadev J, Deng W, Kim H et al.. “Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer.” International journal of radiation oncology, biology, physics (2026). PMID: 42184868 ↗

    L1OTHERCited in: External Beam Radiotherapy (EBRT)
  86. [86]

    Lee SS, Weil CR, Boyd L et al.. “Trends in Intensity Modulated Radiation Therapy Utilization for Definitive Treatment of Intact Cervical Cancer, 2004-2019.” Advances in radiation oncology (2026). PMID: 42183318 ↗

    L2OTHERCited in: External Beam Radiotherapy (EBRT)
  87. [87]

    Shinde P, Ak A, Agarwal P et al.. “Spatially fractionated radiotherapy using straight and bending virtual rods as an alternative for cervical cancer brachytherapy-results from preclinical in-silico dose comparison and quality assurance.” The British journal of radiology (2026). PMID: 42179164 ↗

    L4OTHERCited in: External Beam Radiotherapy (EBRT)
  88. [88]

    Hu L, Li J, Du Y et al.. “Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study.” Journal of gynecologic oncology (2026). PMID: 41381401 ↗

    L1RCTCited in: Brachytherapy, Concurrent Chemoradiation
  89. [89]

    Ebner C, Purtscheller R, Feroz B et al.. “Biopsy-proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome-Retrospective single-center cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 41423908 ↗

    L3COHORTCited in: Brachytherapy
  90. [90]

    Zhou J, Cai J, Li X et al.. “Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41411697 ↗

    L3COHORTCited in: Brachytherapy
  91. [91]

    Cvancarova M, Samuelsen SO, Magelssen H et al.. “Reproduction rates after cancer treatment: experience from the Norwegian radium hospital.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19075285 ↗

    L2OTHERCited in: Brachytherapy
  92. [92]

    Nakashima T, Matsumoto K, Yoshitake T et al.. “Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study.” Japanese journal of radiology (2026). PMID: 41441948 ↗

    L3COHORTCited in: Brachytherapy, Acute and Late Toxicity
  93. [93]

    Liu R, Fan Z, Ma H et al.. “Best evidence summary on sexual health management for patients undergoing intracavitary brachytherapy for gynecological neoplasms.” Frontiers in oncology (2026). PMID: 41695375 ↗

    L5SR_OBSCited in: Brachytherapy
  94. [94]

    Straathof R, Pool LI, van Vliet-Pérez SM et al.. “Clinical factors affecting the therapeutic dose window in cervical cancer brachytherapy: A systematic review and meta-regression.” Brachytherapy (2026). PMID: 41444098 ↗

    L2SR_OBSCited in: Brachytherapy
  95. [95]

    Noordhuis MG, Eijsink JJ, Ten Hoor KA et al.. “Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19920104 ↗

    L2OTHERCited in: Brachytherapy
  96. [96]

    Ilia G, Thomopoulos A, Chronas D. “Preserved Menstruation After Chemoradiotherapy in Stage IIIC1 Cervical Cancer: A Unique Case.” Journal of clinical medicine (2026). PMID: 41753237 ↗

    L4CASE_REPORTCited in: Brachytherapy
  97. [97]

    Zhang L, Ai C, Yu S et al.. “Successful sequential chemo-immunotherapy and reduced-volume brachytherapy for bulky residual cervical tumor after external beam radiotherapy: two case reports.” Frontiers in immunology (2025). PMID: 41346603 ↗

    L4CASE_REPORTCited in: Brachytherapy
  98. [98]

    Vongdala C, Sahat O, Luangxay T et al.. “Types and spatial distribution of cancer cases registered in a national hospital-based registry in the Lao People's Democratic Republic from 2010 to 2024.” BMC public health (2026). PMID: 42050476 ↗

    L2OTHERCited in: Brachytherapy
  99. [99]

    Lissoni AA, Colombo N, Pellegrino A et al.. “A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19181826 ↗

    L1RCTCited in: Concurrent Chemoradiation
  100. [100]

    Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  101. [101]

    Gupta S, Maheshwari A, Parab P et al.. “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29432076 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  102. [102]

    Symonds RP, Gourley C, Davidson S et al.. “Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26474517 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  103. [103]

    Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗

    L1RCTCited in: Concurrent Chemoradiation
  104. [104]

    Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗

    L1TRIAL_NONRANDOMCited in: Concurrent Chemoradiation, Outcomes
  105. [105]

    Tewari KS, Colombo N, Monk BJ et al.. “Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 38095881 ↗

    L1RCTCited in: Concurrent Chemoradiation
  106. [106]

    Thaker PH, Salani R, Brady WE et al.. “A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998970 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemoradiation, Outcomes
  107. [107]

    Tewari KS, Sill MW, Monk BJ et al.. “Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26672085 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  108. [108]

    Li K, Chen J, Hu Y et al.. “Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38048802 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemoradiation
  109. [109]

    Gray HJ. “Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267058 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation, Adjuvant and Palliative RT
  110. [110]

    Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemoradiation
  111. [111]

    Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗

    L2TRIAL_NONRANDOMCited in: Concurrent Chemoradiation, Outcomes
  112. [112]

    Umemiya M, Kou K, Inayama Y et al.. “Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 41612081 ↗

    L1SR_OBSCited in: Concurrent Chemoradiation
  113. [113]

    Long HJ. “Management of metastatic cervical cancer: review of the literature.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17617528 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation
  114. [114]

    Wei S, Li X, Liu Z et al.. “Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial.” Journal of gynecologic oncology (2026). PMID: 41514314 ↗

    L5TRIAL_NONRANDOMCited in: Concurrent Chemoradiation
  115. [115]

    Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation, Outcomes
  116. [116]

    Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation
  117. [117]

    Zhang Y, Meng Y, Shi H et al.. “Prevalence and influencing factors of depressive and anxiety symptoms in cervical cancer patients during the peri-chemoradiotherapy period: A systematic review meta-analysis.” Medicine (2026). PMID: 41559991 ↗

    L1SR_OBSCited in: Concurrent Chemoradiation
  118. [118]

    Zhao X, Singhal A, Park S et al.. “Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress.” Cancer discovery (2024). PMID: 38236062 ↗

    L5OTHERCited in: Concurrent Chemoradiation
  119. [119]

    Ishida S, McCormick F, Smith-McCune K et al.. “Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.” Cancer cell (2010). PMID: 20541702 ↗

    L5OTHERCited in: Concurrent Chemoradiation, Outcomes
  120. [120]

    Sannigrahi MK, Sharma R, Singh V et al.. “Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28143871 ↗

    L5OTHERCited in: Concurrent Chemoradiation
  121. [121]

    Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗

    L1GUIDELINECited in: Adjuvant and Palliative RT
  122. [122]

    Chargari C, Ducassou A, Laville A et al.. “Radiotherapy and brachytherapy for cervical cancer: Recommendations of the Société française de radiothérapie oncologique.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41086563 ↗

    L1GUIDELINECited in: Adjuvant and Palliative RT
  123. [123]

    Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗

    L3OTHERCited in: Adjuvant and Palliative RT
  124. [124]

    Park JY, Kim DY, Kim JH et al.. “Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 20595451 ↗

    L3OTHERCited in: Adjuvant and Palliative RT
  125. [125]

    Bai F, Wu G, Qu X et al.. “Optimal adjuvant radiotherapy strategy for cervical cancer: a multi-center database cohort study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41308331 ↗

    L3COHORTCited in: Adjuvant and Palliative RT
  126. [126]

    Chase DM, Huang HQ, Deng W et al.. “Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).” Gynecologic oncology (2025). PMID: 41056581 ↗

    L1RCTCited in: Adjuvant and Palliative RT
  127. [127]

    Hardie AN, Wenzel HHB, Schnack TH et al.. “Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.” European journal of cancer (Oxford, England : 1990) (2025). PMID: 40795525 ↗

    L2COHORTCited in: Adjuvant and Palliative RT
  128. [128]

    Kidd EA, Siegel BA, Dehdashti F et al.. “Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20308664 ↗

    L2OTHERCited in: Adjuvant and Palliative RT
  129. [129]

    Russo AL, Depauw N, Horick NK et al.. “Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix.” International journal of radiation oncology, biology, physics (2025). PMID: 40089072 ↗

    L4TRIAL_NONRANDOMCited in: Adjuvant and Palliative RT
  130. [130]

    Okuma K, Murakami N, Inaba K et al.. “Gel spacer-assisted salvage brachytherapy for pelvic recurrence after definitive chemoradiotherapy in cervical cancer: A single-institution retrospective study.” Brachytherapy (2025). PMID: 40769797 ↗

    L4COHORTCited in: Adjuvant and Palliative RT
  131. [131]

    Ooko F, Mothiba T, Van Bogaert P et al.. “Access to palliative care in patients with advanced cancer of the uterine cervix in the low- and middle-income countries: a systematic review.” BMC palliative care (2023). PMID: 37726748 ↗

    L2SR_OBSCited in: Adjuvant and Palliative RT
  132. [132]

    Sarfati D, Dyer R, Sam FA et al.. “Cancer control in the Pacific: big challenges facing small island states.” The Lancet. Oncology (2019). PMID: 31395476 ↗

    L5REVIEW_NARRATIVECited in: Adjuvant and Palliative RT
  133. [133]

    Höckel M, Hentschel B, Horn LC. “Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.” The Lancet. Oncology (2014). PMID: 24656439 ↗

    L2OTHERCited in: Adjuvant and Palliative RT
  134. [134]

    Weidhaas JB, Li SX, Winter K et al.. “Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19509178 ↗

    L4OTHERCited in: Adjuvant and Palliative RT
  135. [135]

    Rose PG, Ali S, Watkins E et al.. “Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17502627 ↗

    L1RCTCited in: Acute and Late Toxicity, Outcomes
  136. [136]

    Monk BJ, Sill MW, Burger RA et al.. “Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19139430 ↗

    L4TRIAL_NONRANDOMCited in: Acute and Late Toxicity
  137. [137]

    Chen G, Wang M, Lin E et al.. “Herbal medicines for radiation vaginitis: A systematic review and meta-analysis.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2025). PMID: 41086674 ↗

    L1SR_OBSCited in: Acute and Late Toxicity
  138. [138]

    Takekuma M, Nishio S, Yamaguchi S et al.. “Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.” Journal of gynecologic oncology (2025). PMID: 40968753 ↗

    L1RCTCited in: Acute and Late Toxicity
  139. [139]

    Wang Y, Zhang X, Wang F et al.. “Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 40876576 ↗

    L1RCTCited in: Acute and Late Toxicity
  140. [140]

    Muangwong P, Tharavichitkul E, Thiennimitr P et al.. “Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoing pelvic radiotherapy for gynecologic cancers: a randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40526282 ↗

    L1RCTCited in: Acute and Late Toxicity
  141. [141]

    Chikazawa K, Imai K, Ko H et al.. “Adjuvant chemotherapy after radical hysterectomy yields comparable outcomes to chemoradiation for stage IB2-IIB and IIIC1-2 cervical cancer: a single-center retrospective study.” Journal of gynecologic oncology (2025). PMID: 40114548 ↗

    L3COHORTCited in: Acute and Late Toxicity
  142. [142]

    Hwang JH, Kim B. “Postoperative Urinary Complications in Minimally Invasive Versus Abdominal Radical Hysterectomy: A Meta-Analysis With a Focus on Ureterovaginal Fistula.” Journal of minimally invasive gynecology (2025). PMID: 39710105 ↗

    L2SR_OBSCited in: Acute and Late Toxicity
  143. [143]

    Saini SK, Srivastava S, Goel A et al.. “Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.” International journal of radiation oncology, biology, physics (2026). PMID: 42034194 ↗

    L2SR_OBSCited in: Acute and Late Toxicity
  144. [144]

    Pham TN, Coupey J, Valable S et al.. “Tumor Site-Specific Radiation-Induced Lymphocyte Depletion Models After Fractionated Radiotherapy: Considerations of Model Structure From an Aggregate Data Meta-Analysis.” JCO clinical cancer informatics (2025). PMID: 41118606 ↗

    L2SR_OBSCited in: Acute and Late Toxicity
  145. [145]

    Kelley J, Yao M, Chau D et al.. “Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study.” Gynecologic oncology reports (2025). PMID: 40092738 ↗

    L3COHORTCited in: Acute and Late Toxicity
  146. [146]

    Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗

    L1RCTCited in: Outcomes
  147. [147]

    Nam JH, Park JY, Kim DY et al.. “Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 21841155 ↗

    L2COHORTCited in: Outcomes
  148. [148]

    Ramirez PT, Robledo KP, Frumovitz M et al.. “LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38810208 ↗

    L1RCTCited in: Outcomes
  149. [149]

    Wenzel L, Osann K, Hsieh S et al.. “Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25713429 ↗

    L1RCTCited in: Outcomes
  150. [150]

    Lorusso D, Ferrandina G, Pignata S et al.. “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19605508 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  151. [151]

    Zagouri F, Korakiti AM, Zakopoulou R et al.. “Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis.” Cancer treatment reviews (2019). PMID: 31442939 ↗

    L1SR_OBSCited in: Outcomes
  152. [152]

    Bentivegna E, Gouy S, Maulard A et al.. “Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.” The Lancet. Oncology (2016). PMID: 27299280 ↗

    L2SR_OBSCited in: Outcomes
  153. [153]

    Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗

    L2RCTCited in: Outcomes
  154. [154]

    McCredie MR, Sharples KJ, Paul C et al.. “Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.” The Lancet. Oncology (2008). PMID: 18407790 ↗

    L2COHORTCited in: Outcomes
  155. [155]

    Colombo N, Dubot C, Lorusso D et al.. “Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.” The New England journal of medicine (2021). PMID: 34534429 ↗

    L1RCTCited in: Outcomes
  156. [156]

    Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗

    L1RCTCited in: Outcomes
  157. [157]

    Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗

    L1RCTCited in: Outcomes
  158. [158]

    . “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.” The New England journal of medicine (2007). PMID: 17494925 ↗

    L1RCTCited in: Outcomes
  159. [159]

    Frenel JS, Le Tourneau C, O'Neil B et al.. “Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29095678 ↗

    L2TRIAL_NONRANDOMCited in: Outcomes
  160. [160]

    Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗

    L2TRIAL_NONRANDOMCited in: Outcomes
  161. [161]

    Lan C, Shen J, Wang Y et al.. “Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 33052760 ↗

    L2TRIAL_NONRANDOMCited in: Outcomes
  162. [162]

    Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗

    L1TRIAL_NONRANDOMCited in: Outcomes
  163. [163]

    Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗

    L2TRIAL_NONRANDOMCited in: Outcomes
  164. [164]

    Pennington KP, Urban RR, Gray HJ. “Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659132 ↗

    L5REVIEW_NARRATIVECited in: Outcomes
  165. [165]

    Abu-Rustum NR, Sonoda Y. “Fertility-sparing surgery in early-stage cervical cancer: indications and applications.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147906 ↗

    L2OTHERCited in: Outcomes
  166. [166]

    Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗

    L2TRIAL_NONRANDOMCited in: Outcomes
  167. [167]

    Stevanović S, Helman SR, Wunderlich JR et al.. “A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30518633 ↗

    L2TRIAL_NONRANDOMCited in: Outcomes
  168. [168]

    Mi X, Lin T, Zhu X et al.. “Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42292353 ↗

    L1SR_OBSCited in: Outcomes
  169. [169]

    Zhang D, Meng Y, Dong X et al.. “Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42253994 ↗

    L1SR_OBSCited in: Outcomes
  170. [170]

    Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗

    L1SR_OBSCited in: Outcomes
  171. [171]

    Panczel I, Herold M, Borbenyi E et al.. “Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892820 ↗

    L1SR_OBSCited in: Outcomes
  172. [172]

    Zhou J, Ye W, Ranarisoa SN et al.. “Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 41822503 ↗

    L1SR_OBSCited in: Outcomes
  173. [173]

    Zhuang Q, Liu Y. “Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 41601625 ↗

    L2SR_OBSCited in: Outcomes
  174. [174]

    Shi A, Yerebake M, Du Z et al.. “Acupuncture as Adjunctive Therapy for Cervical Cancer Pain: A Systematic Review and Meta-Analysis.” Journal of pain and symptom management (2026). PMID: 41482014 ↗

    L1SR_OBSCited in: Outcomes
  175. [175]

    Piya IJ, Riya IJ, Sharma V. “Efficacy and safety of immune checkpoint inhibitors with chemoradiotherapy/chemotherapy in locally advanced cervical cancer patients: a systematic review and single-arm meta-analysis.” Journal of gynecologic oncology (2026). PMID: 41267534 ↗

    L1SR_OBSCited in: Outcomes
  176. [176]

    Verleye L, Vergote I, Reed N et al.. “Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG).” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19556323 ↗

    L5REVIEW_NARRATIVECited in: Outcomes
  177. [177]

    Shibata K, Kajiyama H, Ino K et al.. “Twist expression in patients with cervical cancer is associated with poor disease outcome.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 17925286 ↗

    L4OTHERCited in: Outcomes
  178. [178]

    Kim JH, Hwang WY, Choi CH et al.. “Oncologic outcomes and the impact of minimally invasive surgery in early-stage cervical cancer patients undergoing radical trachelectomy: A retrospective multicenter cohort study from the Korean Gynecologic Oncology Group Study (KGOG 1048).” Gynecologic oncology (2026). PMID: 42013607 ↗

    L2COHORTCited in: Outcomes
  179. [179]

    Ventriglia J, Paciolla I, Pisano C et al.. “Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.” Cancer treatment reviews (2017). PMID: 28800469 ↗

    L5REVIEW_NARRATIVECited in: Outcomes
  180. [180]

    Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗

    L1OTHERCited in: Outcomes
  181. [181]

    Kim SS, Shen S, Miyauchi S et al.. “B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32193227 ↗

    L5OTHERCited in: Outcomes

Revision History

All updates applied to this page

Loading revisions…